The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer by Girardi, Michael et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/09/747/9 $8.00
Volume 198, Number 5, September 1, 2003 747–755
http://www.jem.org/cgi/doi/10.1084/jem.20021282
 
747
 
The Distinct Contributions of Murine T Cell Receptor 
 
(TCR)
 
  
 
  
 
and TCR
 
  
 
  
 
T Cells to Different Stages of 
Chemically Induced Skin Cancer
 
Michael Girardi,
 
1 
 
Earl Glusac,
 
1 
 
Renata B. Filler,
 
1 
 
Scott J. Roberts,
 
1
 
Iva Propperova,
 
3 
 
Julia Lewis,
 
1 
 
Robert E. Tigelaar,
 
1,2 
 
and Adrian C. Hayday
 
4
 
1
 
Department of Dermatology and the Yale Skin Diseases Research Core Center, and 
 
2
 
Section of Immunobiology, 
Yale University, New Haven, CT 06520
 
3
 
Department of Dermatology and Venereology, Motal University Hospital, 150 06 Prague 5, Czech Republic
 
4
 
Peter Gorer Department of Immunobiology, Guy’s King’s St. Thomas’ School of Medicine, Guy’s Hospital, 
SE1 9RT London, United Kingdom
 
Abstract
 
Epithelial tissues in which carcinomas develop often contain systemically derived T cell recep-
tor (TCR)
 
  
 
  
 
cells and resident intraepithelial lymphocytes that are commonly enriched in
TCR
 
  
 
  
 
cells. Recent studies have demonstrated that 
 
   
 
cells protect the host against chemi-
cally induced cutaneous malignancy, but the role of 
 
   
 
T cells has been enigmatic, with both
protective and tumor-enhancing contributions being reported in different systems. This study
aims to clarify the contributions of each T cell type to the regulation of squamous cell carci-
noma induced in FVB mice by a two-stage regimen of 7,12-dimethylbenz[
 
a
 
]anthracene initiation
followed by repetitive application of the tumor promoter 12-O-tetradecanoylphorbol 13-acetate.
This protocol permits one to monitor the induction of papillomas and the progression of those
papillomas to carcinomas. The results show that whereas 
 
   
 
cells are strongly protective, the
nonredundant contributions of 
 
   
 
T cells to the host’s protection against papillomas are more
modest. Furthermore, at both high and low doses of carcinogens, 
 
   
 
T cells can contribute to
rather than inhibit the progression of papillomas to carcinomas. As is likely to be the case in humans,
this study also shows that the contribution of T cells to tumor immunosurveillance is regulated
by modifier genes.
Key words: carcinogenesis • squamous cell carcinoma • TCR 
 
  
 
 • TCR 
 
   
 
• immunogenetics
 
Introduction
 
Nonmelanoma skin cancer (NMSC) is the most prevalent
form of malignancy reported among Caucasians, and the
extent to which its development might be regulated by the
immune system is of considerable interest. In support of
such regulation is the fact that iatrogenically immuno-
suppressed organ transplant recipients show 
 
 
 
24-fold sus-
ceptibility to the development of cutaneous squamous cell
carcinoma (SCC), by far the highest alteration of tumor
incidence reported in cases of clinical immunosuppression (1).
Such data drive intense interest in the prospect of immuno-
therapy as a treatment for SCC and other NMSCs.
Nonetheless, it is also reported that the incidence of
SCC is decreased by nonsteroidal antiinflammatory reagents,
such as inhibitors of cyclooxygenase-2, which would be
predicted to decrease immune regulation of tumor tissue
(2, 3). An hypothesis to accommodate the enhanced sus-
ceptibility of immunosuppressed individuals and the pro-
tective effects of antiinflammatory agents is that there are
qualitatively distinct components of the immune system
that de facto inhibit and contribute to tumor development,
respectively. Therefore, one would predict that pharmaco-
logical antiinflammatory agents that preferentially inhibit
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lymphoid cells contributing to tumor development, would
on aggregate display antitumor efficacy.
The concept of different immunological components re-
sponding to tumors finds support in the observation that
many of the epithelia in which carcinomas develop harbor
distinct subsets of T cells, which comprise resident, intraep-
ithelial lymphocytes (IELs) and infiltrating systemic T cells,
respectively (4, 5). Considering the large surface area of ep-
ithelia, it has been proposed that IELs comprise somewhere
between one quarter and one half of the body’s T cells.
When cross compared, IELs and systemic T cells display
highly distinct gene expression profiles and T cell receptor
usage (6, 7). For example, whereas the murine and human
systemic T cell compartments are dominated by TCR
 
  
 
 
 
cells, the IEL repertoires are disproportionately enriched in
TCR
 
  
 
  
 
cells (5).
Murine skin is a striking example of IEL and systemic T
cell coexistence. The constitutive IEL repertoire comprises
a dendritic epidermal T cell (DETC) subset of which
 
 
 
95% of cells express a single, homogeneous 
 
   
 
TCR (8).
At the same time, the epidermis harbors tissue-associated
DCs, known as Langerhans cells, which process antigens
encountered in the skin and migrate to the local LNs,
where they prime and provoke skin infiltration by antigen-
reactive systemic 
 
   
 
T cells. Recently, we reported that
TCR
 
  
 
  
 
DETCs actively suppress the migration into the
skin of 
 
   
 
T cell–dependent cellular infiltrates (9). This ex-
ample of functional interaction between the “local” and
systemic components of the immune system suggests that
DETCs can protect epithelial integrity from internal dis-
ruption. An additional protection of epithelial integrity by
DETCs is suggested by reports that DETCs produce locally
active keratinocyte growth factor (10).
Relative to their immunocompetent counterparts,
TCR
 
 
 
    
 
mice were also demonstrated to be highly sus-
ceptible to the development of SCC induced by any of
three regimens (11). As a potential underlying mechanism,
isolated DETCs were shown to lyse SCC cells dependent
on the engagement of two 
 
   
 
cell surface receptors,
TCR
 
   
 
and NKG2D (11). Although TCR
 
  
 
    
 
mice
were likewise susceptible to some regimens of SCC induc-
tion (11), this was not universal, raising the possibility that
the distinct contribution of different T cell subsets to tumor
regulation is manifest in murine skin. Consistent with this,
Siegel et al. (12) reported that mice expressing a transgenic
TCR
 
   
 
showed an increased incidence of skin papillomas
when the 
 
   
 
T cells were preactivated by immunization
with antigenic peptide. Likewise, it was recently reported
that CD4
 
  
 
   
 
T cells, apparently responding to bacterial
infection, can cause tissue disruption that promotes the
progression of skin tumors induced by transgenic onco-
genes (13). The concept that some T cell responses to
chemical carcinogenesis might promote tumor develop-
ment is tested more generally in this paper, in which sub-
stantial numbers of mice are subjected to a two-stage
chemical carcinogenesis regimen in which the induction of
papillomas and the progression to carcinomas are separately
monitored. The FVB mouse strain used in this paper has
 
previously been shown to be highly susceptible to chemi-
cally induced SCC (14). The tumors that develop are
entirely syngeneic, theoretically limiting conventional,
MHC-restricted 
 
   
 
T cell recognition to the expression of
tumor antigen–derived peptides. We find that 
 
   
 
cell defi-
ciency causes a profound increase in the incidence of papil-
lomas and carcinomas. By contrast, there was a less pro-
nounced effect of 
 
   
 
T cells on papilloma development,
and most strikingly, clear evidence that the presence of 
 
  
 
T cells promotes the progression of papillomas to carcino-
mas. Additionally, we show that the immunosurveillance of
tumors by 
 
   
 
cells is under genetic regulation.
 
Materials and Methods
 
Animals.
 
TCR
 
 
 
    
 
and TCR
 
 
 
    
 
C57BL/6 mice (The Jack-
son Laboratory) were backcrossed to FVB mice (Taconic) for 11
generations each. FVB.
 
 
 
   
 
 
 
    
 
mice were produced by first
crossing FVB.
 
 
 
    
 
with FVB.
 
 
 
    
 
mice to obtain double het-
erozygotes, and then intercrossing these animals to obtain the
double knockouts. For genetic studies, FVB.
 
 
 
    
 
mice were
mated with C57BL/6.
 
 
 
    
 
mice to produce both (FVB 
 
 
 
C57BL/6)F
 
1
 
.
 
 
 
    
 
and (C57BL/6 
 
  
 
FVB)F
 
1
 
.
 
 
 
    
 
offspring. F
 
1
 
.
 
 
 
   
 
mice were then intercrossed to produce F
 
2
 
.
 
 
 
    
 
offspring, and
were backcrossed to FVB.
 
 
 
    
 
to produce (F
 
1
 
 
 
  
 
FVB)BC.
 
 
 
   
 
and (FVB 
 
  
 
F
 
1
 
)BC.
 
 
 
    
 
animals. Mice were kept in filter-topped
cages with sterilized food and water, and autoclaved corncob
bedding, which was changed at least once weekly. The facility is
accredited by the American Association for Accreditation of Lab-
oratory Animal Care.
 
Chemical Carcinogens.
 
Chemicals were obtained from Sigma-
Aldrich. 7,12-dimethylbenz[
 
a
 
]anthracene (DMBA) was dissolved
in acetone at a concentration of 200 nmol per 100 
 
 
 
l. 12-O-tet-
radecanoylphorbol 13-acetate (TPA) was dissolved in 100% etha-
nol at a concentration of 5 nmol per 100 
 
 
 
l (0.05 mM), or 40
nmol per 100 
 
 
 
l (0.4 mM).
 
Fetal Liver Hematopoetic Stem Cell (FLHSC) Reconstitution.
 
Newborn TCR
 
 
 
    
 
mice were reconstituted with peripheral 
 
  
 
T cell progenitors from FLHSCs of FVB mice as follows: day
13.5 fetal livers were harvested and gently pressed between the
frosted edges of two glass slides, releasing the cells into ice-cold
HBSS containing 4 mM Hepes buffer and antibiotics. Fetal liver
cells were filtered through nylon mesh (Nytex cloth 88/42;
Tetko Inc.) to remove debris and give single cell suspensions,
washed twice with HBSS, and resuspended at appropriate con-
centrations in sterile PBS before intraperitoneal injection at 3 
 
 
 
10
 
6 
 
cells in 30 
 
 
 
l PBS per newborn TCR
 
 
 
    
 
recipient.
 
Two-Stage Chemical Carcinogenesis Protocol.
 
Initiation was per-
formed by pipette application of 200 nmol of DMBA, followed
by weekly treatment with 5 or 40 nmol of the tumor promoter
TPA in acetone onto the back skin of 8-wk-old mice, 1 wk after
shaving hair with electric clippers followed by depilatory cream.
(For the experiment shown in Fig. 2 C, a hand razor alone was
used to remove the hairs on all mice).
 
Tumor Scoring and Histology.
 
Mice were assessed every 1–2
wk for tumor development, and tumors were counted, measured,
and scored as clinically apparent papillomas (typically well-demar-
cated, symmetrical, pedunculated, or dome-shaped papules, with-
out erosion or ulceration), or clinically apparent carcinomas
(poorly demarcated, asymmetrical, nonpedunculated, or dome-
shaped papules with erosion or ulceration). Tumors were evalu-
ated by visual inspection by an observer blinded to the experi-T
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mental group. To assess the validity of the clinical scoring system,
three tumors from each type (papilloma and carcinoma) and size
category (
 
 
 
1 mm
 
2
 
, 
 
 
 
4 mm
 
2
 
, 
 
 
 
9 mm
 
2
 
, and 
 
 
 
16 mm
 
2
 
; see Re-
sults) were submitted for histologic review by a dermatopatholo-
gist blinded to the clinical score. Of 18 tumors reviewed, there
was 100% concordance between the clinical and histological as-
sessments (representatives are depicted in Fig. 2 A). At the con-
clusion of experiments, tumors were excised, formalin fixed, par-
affin embedded, and 5-
 
 
 
m sections were hematoxylin and eosin
stained and examined (by E. Glusac) for histologic findings.
 
Statistical Analysis.
 
Statistical significance was evaluated by
two-tailed, unpaired Student’s 
 
t
 
 test, or nonparametric analysis if
standard deviations were significantly different between the two
compared groups.
 
Results
 
Tumor Incidence Is Increased and Tumor Onset Is More Rapid
in TCR
 
 
 
    
 
and TCR
 
 
 
   
 
 
 
    
 
Mice.
 
To induce cutane-
ous SCC, FVB mice were painted with a single initiating
application of 200 nmol DMBA, followed by weekly treat-
ment with a low dose (5 nmol) of the tumor promoter
TPA. Each experimental group comprised 15 mice, in
which the development of palpable tumors (
 
 
 
1 mm) was
recorded over time. Tumor size was classified as T1   1
mm2, T2   4 mm2, T3   9 mm2, and T4   16 mm2 (Ta-
ble I). In WT mice, tumors first became visible between 11
and 13 wk after initiation (Fig. 1), and then the incidence
increased slowly but steadily until 17 wk, when the experi-
ment was curtailed for humane reasons. By that time, 13
out of 15 mice (87%) recorded 60 tumors (mean 4.0  
0.9/mouse; Fig. 1 and Table I.
In TCR     mice, two tumors appeared before any
were detected in WT mice, but thereafter tumor develop-
ment was comparable in the two strains. By 17 wk, 10 out
of 15 mice collectively bore 86 tumors, yielding an average
of 5.7   1.8 tumors per mouse, which was not significantly
different from WT (P   0.08; Fig. 1 and Table I). By con-
trast, a substantially greater susceptibility to tumor induc-
tion was shown by TCR     mice. Tumors first appeared
 1 mo before one was detected in WT mice, and then tu-
mor incidence increased steeply between 11 and 13 wk, af-
ter which the increase was steady but less dramatic (Fig. 1).
By 17 wk, 100% of TCR     mice bore 245 tumors (mean
16.3   2.3 tumors per mouse, greater than fourfold higher
incidence than WT; P [     vs. WT]   0.0000064, P [    
vs.     ]   0.00015). These data are consistent with and
expand the reported high susceptibility of TCR     mice
to SCC (11) and emphasize the inability of the    T cells
in TCR     mice to effectively control chemically induced
tumor incidence in the absence of    cells.
The highest susceptibility to tumor development was
shown by TCR         mice lacking both    cells and
   T cells (Fig. 1). The appearance of tumors occurred no
earlier than that in TCR     mice, but the rise in tumor
development between 11 and 13 wk was even steeper. By
17 wk, 100% of TCR         mice collectively bore 509
tumors (mean 33.9   1.8 per mouse; Fig. 1 and Table I.
This incidence (greater than eightfold increase over WT;
P   10 10) significantly exceeded that in all other strains.
Collectively, these data demonstrate that murine    cells
play a significant role in down-regulating chemically in-
Table I. Tumor Sizes at Weeks 13, 15, and 17 after DMBA Initiation
WK 13 WK 15 WK17
T1 T2 T3 T4 Percent Lg. T1 T2 T3 T4 Percent Lg. T1 T2 T3 T4 Percent Lg.
WT 21 7 1 0 27.6 36 14 1 0 29.4 36 18 4 2 40.0
     33 19 2 0 38.9 31 29 5 3 54.4 30 38 6 12 65.1
     72 69 13 2 53.2 33 130 17 3 80.7 57 142 36 10 76.7
         183 144 11 0 45.9 113 262 11 9 73.2 181 282 33 13 64.4
Percent Lg., percent tumors  T2; where 1 mm2   T1   4 mm2   T2   9 mm2   T3   16 mm2   T4.
Figure 1. Rapid tumor onset and increased tumor incidence in
TCR     and TCR         mice. Under a two-stage chemical carcino-
genesis protocol of initiation with 200 nmol DMBA and weekly applica-
tion of (low dose) 5 nmol TPA, WT (w.t.) and T cell–deficient mice
were followed for the development of all cutaneous tumors (papillomas
or carcinomas  1 mm; see Fig. 2 and Table II for breakdown). Although
TCR     mice (deficient in only    T cells) showed no significant dif-
ference in tumorigenesis relative to WT mice, TCR     mice (deficient
in    T cells) and TCR         mice (deficient in both    and    T
cells) exhibited an earlier onset and marked increase in tumor develop-
ment. *, P   0.0001 for          and      versus WT or     .T
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duced cutaneous tumorigenesis, both in terms of time of
onset and cumulative tumor incidence. Indeed, at every
time point, the fraction of tumors that were large in size
was greatest in TCR     mice (Table I and see below).
The prolific occurrence of tumors in TCR         mice
lacking all T cells, relative to the incidence in TCR    
mice, seemingly demonstrates that     T cells can also
down-regulate tumor development, despite the fact that
the TCR     mouse is not significantly more susceptible
to tumor development than its WT FVB counterpart. One
interpretation would be that in TCR     mice,    cells
readily compensate for most of the antitumor activities of
   T cells, whereas in the TCR     mice there is some ca-
pacity of    T cells to substitute for some of the roles of   
cells. Hence, because it lacks any T cell activity, the
TCR         mouse shows an exaggerated defect in tu-
mor surveillance. This capacity for one T cell subset to
compensate to varying degrees for the absence of another
was previously evident in reports of aggressive, transplant-
able B cell lymphomas that develop in fas-deficient mice
lacking all T cells, but not in fas-deficient mice that lack
only a single T cell subset (15).
Morphologic Tumor Progression Is Inhibited by    Cells and
Enhanced by    T Cells. Developing papillomas may re-
gress, increase in size while retaining their overall pheno-
type, or show progression to irregularly shaped carcinomas
that penetrate the basement membrane, invading the der-
mis. The third of these outcomes constitutes the most se-
vere pathology, yet the factors that regulate the respective
outcomes are poorly understood. To determine whether
there is an immunological contribution to tumor progres-
sion, the relative numbers of papillomas versus carcinomas
Figure 2. Morphologic assess-
ment of tumor development in T
cell–deficient mice. Tumors that de-
veloped under two-stage chemical
carcinogenesis (refer to Fig. 1) were
scored as clinically apparent papillomas
(P) or carcinomas (C), as described
in Materials and Methods. (A) He-
matoxylin and eosin–stained sections
of representative tumors were ob-
tained and typical examples are
shown. This papilloma (P1; see text
for scoring index) exhibited a sym-
metric outline, acanthosis, and papil-
lomatosis ( 40), with uniform kera-
tinocytes with moderately abundant
cytoplasm and small round nuclei
( 100). This early carcinoma (C2)
exhibited an asymmetric outline and
expansion of neoplastic follicle-like
structures composed of atypical epi-
thelium ( 40). There was haphazard
infiltration of the dermis by pleo-
morphic keratinocytes with increased
nuclear/cytoplasmic ratio ( 100).
This later stage carcinoma (C3) ex-
hibited a poorly organized, asym-
metric pattern of growth ( 40)
comprised of atypical keratinocytes
aggregated around vascular connec-
tive tissue cores ( 100). (B) Papil-
loma and carcinoma development
for the experiment depicted in Fig. 1
at 17 wk. *, P   0.05; **, P   0.01;
***, P   0.005; ****, P   0.001. (C)
Papilloma and carcinoma develop-
ment in a second independent ex-
periment at study termination. n.d.,
not done. (D) Tumor appearance of
two representative mice from each
of the TCR     and TCR        
groups.T
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were scored in each experimental group. Tumors scored as
papillomas were well-demarcated, symmetrical, peduncu-
lated, or dome-shaped papules, without erosion or ulcer-
ation. Tumors scored as carcinomas were poorly de-
marcated, asymmetric, nonpedunculated, or dome-shaped
papules, with erosion or ulceration (Fig. 2 A). To be con-
sistent with the tumor size classification (Table I), carcino-
mas were classified as: C2   4 mm2, C3   9 mm2, and
C4   16 mm2 (no carcinoma was  4 mm2; Table II).
By 13 wk, WT mice displayed 29 papillomas and 0 car-
cinoma, whereas by 17 wk, the same mice displayed 45
papillomas and 15 carcinomas, giving a “carcinoma/papil-
loma ratio”   0.33 (Table II and Fig. 2 B). In TCR    
mice, the progression to carcinomas was similar to that in
WT mice. At 13 wk, there were 53 papillomas and 1 carci-
noma (Table II), whereas by 17 wk, there were 59 papillo-
mas and 27 carcinomas (carcinoma/papilloma ratio   0.46;
Table II and Fig. 2 B.
By contrast, the greatly enhanced susceptibility of
TCR     mice to tumor development was also manifest in
an increased progression of tumors to carcinomas. By 15
wk,  40% (73 out of 183) of tumors were carcinomas,
compared with  20% in WT mice and TCR     mice
(Table II). By 17 wk, carcinomas (123) were as frequent as
papillomas (122; Table II and Fig. 2 B). The resulting car-
cinoma/papilloma ratio ( 1.01) was the only instance in
which the ratio exceeded 1. Of note, although TCR    
      mice developed many more tumors than other
strains, they primarily remained as papillomas (Table II and
Fig. 2 B). At 15 wk, the carcinoma/papilloma ratio
( 0.19) was similar to that in WT and TCR     mice, and
by 17 wk, it remained at a similar level (0.21), approxi-
mately fivefold less than that in TCR     mice (Table II
and Fig. 2 B). The contrasting appearance of tumor devel-
opment in TCR     mice and TCR         mice is de-
picted in Fig. 2 D.
Collectively, the data demonstrate that    cells act both
to prevent tumor development (i.e., papilloma formation)
and inhibit progression to carcinoma, whereas the absence
of    T cells in TCR         mice reduces tumor pro-
gression relative to that in TCR     mice. To test this fur-
ther, an additional experiment was undertaken, this time
comparing tumor development and progression over a 15-
wk period in 15 mouse groups of WT, TCR    , and
TCR         strains. Certain parameters were different in
the second experiment (Fig. 2 C). Both males and females
were used (whereas in the first experiment age-matched fe-
males were used), a different stock of DMBA was used, and
a hand razor was used for the preparation of the skin for
carcinogen application (whereas in the first experiment an
electric razor plus depilatory cream was used). For all or any
of these reasons, the overall incidence of tumors was less,
but despite these differences, the pattern of the results ob-
tained was identical. The susceptibility to papilloma forma-
tion was again in the order WT    TCR       TCR    
     mice, whereas the progression of tumors to carcinomas
in TCR         mice was again less than that in TCR    
mice (Fig. 2 C). The carcinoma/papilloma ratios were
TCR       0.33 and TCR           0.07. Thus, the ra-
tio in TCR          mice was approximately fivefold
lower than that in TCR     mice in both experiments.
Tumor Regulation by    T Cells at Higher Doses of Carcino-
gens. To examine further the regulation of tumor pro-
gression by    T cells, experiments were undertaken in
which tumor promotion was provoked by weekly applica-
tion of 40 nmol (rather than 5 nmol) of TPA to WT and
TCR     mice. Under such conditions, WT mice develop
substantially more tumors than when lower doses of TPA
are used. Under these conditions, the tumor incidence in
TCR     mice was substantially lower than that in WT
mice (12.7   1.7 vs. 20.9   1.9 at 15 wk; P   0.0015; not
depicted), and represented a markedly smaller tumor area
per mouse (68.2   9.5 mm2 vs. 203.1   25.2; P   0.001;
Fig. 3 A). Furthermore, TCR     mice were approxi-
mately fivefold less susceptible to tumor progression to car-
cinomas (2.35   0.5 per mouse vs. 11.8   1.1 cm2; P  
0.0001) at 15 wk (Fig. 3 B). The contrasting appearance of
tumor development in WT and TCR     mice is depicted
in Fig. 3 C.
Although the TCR mutant mice used in this study were
extensively backcrossed to the FVB strain, it remained im-
portant to show that the heightened incidence of tumor
progression in the TCR     mouse was due primarily to
their lack of     T cells. Therefore, TCR     mice were
Table II. Tumor Morphologies at Weeks 13, 15, and 17 after DMBA Initiation
WK 13 WK 15 WK 17
Papa C2 C3 C4 C/Pb Papa C2 C3 C4 C/Pb Papa C2 C3 C4 C/Pb
WT 29 0 0 0 0.00 42 8 1 0 0.21 45 9 4 2 0.33
     53 0 1 0 0.02 53 7 5 3 0.28 59 9 6 12 0.46
     152 0 2 2 0.03 110 56 14 3 0.66 122 77 36 10 1.01
         328 2 8 0 0.03 332 43 11 9 0.19 421 45 30 13 0.21
aPap, total papillomas.
bC/P, carcinoma/papilloma ratio.T
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reconstituted at birth with day 13.5 FLHSCs from WT
FVB donors. Flow cytometry of the spleens of the reconsti-
tuted mice (n   13) showed substantial repopulation of pe-
ripheral    T cell compartment at 6 wk of age (mean 43.0  
5.2%; Fig. 3 D), whereupon the mice were subjected to
two-stage carcinogenesis using 40 nmol TPA. Compared
with mock-reconstituted TCR     mice, the    T cell–
reconstituted TCR      demonstrated an approximately
threefold higher tumor area (147.1   32.4 vs. 43.3   10.1
mm2; P   0.0025; Fig. 3 E) and threefold greater number
of carcinomas per mouse (4.6   1.0 vs. 1.4.1   0.4 cm2;
P   0.0025; Fig. 3 F) at 15 wk after initiation. These data
show that mice that harbor    T cells are more susceptible
to tumor progression than mice of identical genotype that
lack    T cells.
Genetic Modifiers Regulate Tumor Surveillance by    Cells.
Having established that    T cell deficiency increases the
susceptibility of FVB mice to SCC, we examined whether
this observation might be used to reveal additional genetic
modifiers of tumor development. Therefore, the DMBA
TPA (5 nmol) regimen for SCC induction was applied to a
total of 483 WT and TCR     FVB mice, WT and
TCR     C57BL/6 (B6) mice, and intercrosses thereof.
The data confirmed that FVB is more susceptible than B6
Figure 3. Marked decrease in tu-
mor burden and progression in
TCR     mice. Under a two-stage
chemical carcinogenesis protocol of
initiation with 200 nmol DMBA
and weekly application of (high
dose) 40 nmol TPA, WT (w.t.) and
TCR     mice were followed for
the development of tumors ( 1 mm).
TCR     mice deficient in     T
cells demonstrated a markedly lower
(A) tumor area and (B) carcinoma
development. (C) Clinical tumor
appearance of two representative
mice from each of the WT and     
groups. (D) Representative flow cy-
tometric analysis for the presence of
    (H57) T cells in the spleens
of 6-wk-old TCR     mice, WT
mice, and TCR     mice reconsti-
tuted at birth by intraperitoneal in-
jection of day 13.5 FLHSCs. (E and
F) Reconstituted TCR      mice
(          T cells) demonstrated a
higher tumor area (E) and greater
rate of carcinoma formation (F) than
TCR     mice. *, P   0.02; **, P  
0.01; ***, P   0.005.T
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to chemical induction of SCC (Fig. 4; reference 14).
They  also confirmed the greater susceptibility of the
FVB.TCR     mouse. However, this increased suscepti-
bility was not apparent in either B6.TCR     mice or in
(B6   FVB)F1.TCR     mice (Fig. 4), in both of which
tumor resistance is high. Thus, the powerful contribution
of    cells to SCC regulation is a feature of FVB animals
that are highly susceptible to SCC. Because no B6.TCR    
mice showed more than two tumors, we operationally
defined enhanced susceptibility as mice bearing more than
two 2 tumors. Provocatively, 26.2% of (B6    FVB)
F2.TCR     mice and 46.3% of (B6   FVB)F1.TCR    
mice backcrossed to FVB showed enhanced susceptibility.
In the case that a single gene segregating between B6 and
FVB mice regulates the susceptibility to    deficiency, the
expected frequencies would be 25% in the F2 mice and
50% in the backcross mice. Although it is likely that modi-
fier genes might be influencing carcinogenesis in this sys-
tem via diverse mechanisms (e.g., susceptibility to mu-
tagenesis by DMBA, susceptibility to irritancy by TPA),
future attempts to map those genes may elucidate factors
that compensate for local T cell immunosurveillance in
highly tumor-resistant hosts.
Discussion
This extensive study of cutaneous malignancy induced at
each of two doses of chemical carcinogens in WT and T
cell–deficient FVB mice has demonstrated that the immune
surveillance of tumor development can be classified into
qualitatively distinct immunologic components. Whereas   
cells are protective against chemically induced SCC, the
nonredundant contribution of     T cells to protection
against low doses of carcinogens is more modest (Fig. 1).
Moreover, at higher doses of carcinogens, TCR     mice
are more resistant than WT mice to papillomas (Fig. 3). This
failure of    T cells to contribute to host protection was
most obvious when scoring the conversion of papillomas to
carcinomas, which was de facto promoted by    T cells,
particularly under conditions in which the number of pre-
cursor lesions (i.e., papillomas) was high. This was seen in
four experiments: two independent experiments in which
slightly different protocols were used to apply low doses of
carcinogens to TCR         mice versus TCR     mice
(Fig. 2, B and C), one experiment in which high dose car-
cinogens were applied to TCR     mice versus WT mice
(Fig. 3 B), and one experiment in which high dose carcino-
gens were applied to TCR     mice versus TCR     mice
reconstituted with    T cells (Fig. 3, E and F).
Clearly,    T cells often display protective antitumor ac-
tivity, as in the antigen-specific targeting of tumor-asso-
ciated antigens in human melanoma (16, 17), and the
decreased susceptibility to methylcholanthrene-induced
NMSC in mice lacking    T cells (11). Therefore, it will
be important to determine the factors that regulate whether
on aggregate    T cells inhibit or promote tumor develop-
ment. One factor might be the immunogenicity of a tumor.
Melanomas, for example, might be sufficiently immuno-
genic to offer myriad targets to systemic    T cells. By con-
trast, SCC induced in syngeneic hosts by chemicals that act
with two-stage kinetics might be less immunogenic. Indeed,
Williams et al. (18) reported that such tumors failed to acti-
vate protective systemic T cell responses, even after experi-
mental up-regulation of costimulator molecules. In such
cases,    T cell involvement might be tumor antigen non-
specific, for example, as a response to local inflammation,
and might promote tumor growth by the secretion of large
amounts of cytokines and metalloproteinases (13, 19). Re-
gardless of the mechanisms involved, the data presented
here may aid immunotherapy strategies by emphasizing that
enhanced systemic T cell activation might be most effective
against tumors at the early stages of their development. As a
tumor progresses, treatments designed to enhance systemic
T cell responses may show more variable efficacy.
At the same time, it would seem important not to ignore
the contribution to tumor surveillance of    cells, and pos-
sibly other locally acting, nonconventional T cells that may
resemble them (5, 6). The efficacy of    cells in inhibiting
SCC may reflect the fact that the tumors initiate in a region
rich in TCR    IELs. Thus, the anatomical site of tumor
development will probably dictate the nature of the im-
mune response best equipped to attack the tumor. A corre-
sponding protective T cell compartment in human epider-
mis has not been reported, although a unique TCR   
repertoire in human dermis was recently described (20).
Moreover, the human gut is known to be rich in both sys-
temic T cells and IELs, including    cells, which have been
reported to attack human bowel carcinomas expressing the
MHC class IB molecule, MICA (21). Thus, the protective
Figure 4. Tumor development in crosses of susceptible FVB.TCR    
with resistant C57BL/6.TCR     mice. FVB.TCR     (FVB.    ) and
C57BL/6.TCR     (B6.    ) mice were bred to produce F1.    , F2.    ,
and (F1   FVB) backcross (BC).     offspring. Under a two-stage chem-
ical carcinogenesis protocol of initiation with 200 nmol DMBA and
weekly application of (low dose) 5 nmol TPA, mice were followed for
the development of all cutaneous tumors (papillomas or carcinomas  1
mm) at week 16 after DMBA initiation. The mean number   standard
deviation of total tumors per animal for each group is represented. Al-
though none of the B6.     mice developed more than two tumors,
46.3% of the BC.     and 26.2% of the F2.     mice developed more
than two tumors.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Distinct Roles of    and    T Cells in Carcinogenesis 754
effects of local T cells described here may provide a tracta-
ble animal model for the surveillance of human carcinomas.
The capacity of TCR    IELs to target MHC class IB
molecules such as MICA, might be particularly effective
against tumors that have lost expression of conventional
MHC antigens, a common clinical problem.
As well as targeting tumors directly, the effects of local T
cells might be multifaceted, because the fact that DETC are
potent suppressors of    T cell–mediated inflammation of
the skin (9) strongly suggests that local T cells might reduce
the potential for    T cells to promote carcinoma forma-
tion. It is likewise possible that locally resident and/or infil-
trating T cell subsets may directly modify (e.g., augment or
reduce) the proinflammatory effects of the applied TPA.
The potentiation of environmental carcinogens might be
one mechanism by which T cells regulate carcinogenesis in
humans, although evidence that    T cells may promote
tumor development has additionally been reported in sys-
tems that do not involve chemical carcinogens (12, 13, 19).
Many genes influence skin carcinogenesis in mice (as is
the case in humans; 14), and we have shown in this paper
that the increased susceptibility to tumor development seen
in TCR     mice is dependent on modifier genes found on
the FVB background versus the C57BL/6 background.
Those genes can now be identified. Nonetheless, their exist-
ence raised the formal possibility that genes that cosegre-
gated with the disrupted TCR  locus during the backcross-
ing of the TCR mutant mice to FVB may have contributed
to the observed decrease in tumor progression in TCR    
FVB mice relative to WT FVB (Fig. 3). This possibility was
excluded by showing that the rates of tumor progression in
TCR     mice could be substantially increased by reconsti-
tution with peripheral    T cells without affecting any other
genes. Hence, in this model, the presence of    T cells is a
primary determinant of enhanced tumor progression.
In sum, the design and application of appropriate immu-
notherapy regimens might usefully be informed by classify-
ing types of tumors according to their anatomical site, their
immunogenicity, their stage of development, and the ge-
netics of the host. Indeed, effective immunosurveillance
might be most relevant in hosts who are genetically predis-
posed to tumor susceptibility, whereas in more resistant
hosts, the action of other genes may substitute for immu-
nosurveillance. Such genetic influences are modeled in this
paper by the different dependence of B6 and FVB mice,
respectively, on tumor surveillance by TCR   cells. The
ongoing studies to identify the gene(s) underlying this dif-
ference may prove useful in elucidating factors that under-
pin the significance of immunosurveillance in humans.
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